Hypoxia-activated ROS burst liposomes boosted by local mild hyperthermia for photo/chemodynamic therapy.

Single reactive oxygen species (ROS)-mediated therapy, photodynamic therapy (PDT) or chemodynamic therapy (CDT) is severely hindered in hypoxic solid tumor. Herein, to address the urgent challenge, a hypoxia-activated ROS burst liposome has been fabricated to achieve synergistic PDT/CDT that is initiated by the structural dissociation of poly(metronidazole) liposome in hypoxic tumor microenvironment (TME). The therapeutic enhancement of our ROS-blasting treatment is simultaneously regulated by external light-initiated PDT and endogenous iron oxide nanoclusters-triggered CDT, which is synergistically boosted and amplified by localized mild hyperthermia under 808/660 nm coirradiation.

Near-infrared light-activated red-emitting upconverting nanoplatform for T-weighted magnetic resonance imaging and photodynamic therapy.

Unlabelled: Photodynamic therapy (PDT) has increasingly become an efficient and attractive cancer treatment modality based on reactive oxygen species (ROS) that can induce tumor death after irradiation with ultraviolet or visible light. Herein, to overcome the limited tissue penetration in traditional PDT, a novel near-infrared (NIR) light-activated NaScF: 40% Yb, 2% Er@CaF upconversion nanoparticle (rUCNP) is successfully designed and synthesized. Chlorin e6, a photosensitizer and a chelating agent for Mn, is loaded into human serum albumin (HSA) that further conjugates onto rUCNPs.

pH-Responsive Magnetic Mesoporous Silica-Based Nanoplatform for Synergistic Photodynamic Therapy/Chemotherapy.

By overcoming drug resistance and subsequently enhancing the treatment, the combination therapy of photodynamic therapy (PDT) and chemotherapy has promising potential for cancer treatment. However, the major challenge is how to establish an advanced nanoplatform that can be efficiently guided to tumor sites and can then stably release both chemotherapy drugs and a photosensitizer simultaneously and precisely. In this study, which considered the possibility and targeting efficiency of a magnetic targeting strategy, a novel FeO@mSiO(DOX)@HSA(Ce6) nanoplatform was successfully built; this platform could be employed as an efficient synergistic antitumor nanoplatform with magnetic guidance for highly specific targeting and retention.

Application of nanosized Fe3O4 in anticancer drug carriers with target-orientation and sustained-release properties.

The purpose of this study was to prepare human serum albumin (HSA) microspheres with Fe(3)O(4) magnetic nanoparticles for tumor target therapy. Fe(3)O(4) was obtained by liquid-phase coprecipitation; HSA-coated magnetic particles were attained by solidification at high temperature. The result was that nanosized Fe(3)O(4) is a cubic crystal by XRD and the average size is 18.